Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy

Background Hypercalcemia of malignancy (HCM), a major metabolic complication of cancer, is often managed with bisphosphonates (BP) and, increasingly, with denosumab. We aimed to compare the effectiveness and safety of denosumab with that of BP, with or without calcitonin, in treating HCM. Methods Th...

Descripció completa

Dades bibliogràfiques

Autors principals:	Sung Hye Kong, Seung Shin Park, Jung Hee Kim, Sang Wan Kim, Se Hyun Kim, Jee Hyun Kim, Chan Soo Shin
Format:	Artigo
Idioma:	Inglês
Publicat:	Korean Endocrine Society 2025-04-01
Col·lecció:	Endocrinology and Metabolism
Matèries:	calcitonin denosumab diphosphonates hypercalcemia safety treatment outcome
Accés en línia:	http://e-enm.org/upload/pdf/enm-2024-2132.pdf
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!